3.8 Article

Extracorporeal life support in primary transplant failure: what are the options?

Journal

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00398-022-00546-2

Keywords

Heart transplantation; Ventricular assist device (left); Graft failure; Extracorporeal membrane oxygenation (ECMO); Heart failure

Ask authors/readers for more resources

Heart transplantation is the most effective treatment for terminal heart failure, with over 4000 adult heart transplantations performed annually worldwide. Primary graft dysfunction occurs within 24 hours after transplantation and is influenced by various risk factors. Treatment involves supportive care, inotropes or phosphodiesterase inhibitors, and mechanical circulatory support for severe cases. Early identification of indications is crucial for improving outcomes and shifting the focus from bridging to successful weaning from support.
Heart transplantation (HTx) is still the gold standard in terminal heart failure. Each year, more than 4000 adult heart transplantations are performed worldwide. Despite significant advances in perioperative management during the last 4 decades, the 30 day mortality is still at 5-10% due to early graft failure. Primary graft dysfunction (PGD) occurs within the first 24 h after heart transplantation and is manifested as right, left or biventricular dysfunction. The etiology is not limited to a single cause but instead depends on a multitude of donor-related and recipient-related risk factors. Furthermore, the transplantation process itself leads to an array of negative influences on the graft, such as catecholamine excess during brain death, cold and warm ischemia and reperfusion injury. Treatment of PGD is primarily supportive and necessitates further escalation according to clinical requirements. First-line treatment is inotropes or phosphodiesterase inhibitors. In isolated right ventricular (RV) PGD nitrous oxide can be used to lower pulmonary vascular resistance and RV afterload. Severe cases of PGD require the use of mechanical circulatory support (MCS) to achieve ventricular unloading. The indications should be set as early as possible, as this can improve the efficacy and outcome. In contrast to previous treatment strategies, the current goal of treatment has shifted from bridging to retransplantation to successful weaning from MCS, while preserving end organ function as much as possible.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available